MartinRFarlowMD

Professor and Vice Chairman of Research, Department of Neurology; Core Leader, IADC Clinical Core

Dr. Farlow is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

PubMed

Journal Articles

A Review of Dementia with Lewy Bodies' Impact, Diagnostic Criteria and Treatment
Jared R. Brosch, Martin R. Farlow, Neurology and Therapy
The Cholinergic System in the Pathophysiology and Treatment of Alzheimer’s Disease
George T Grossberg, Peter J Snyder, Martin R Farlow, Brain

Lectures

The Treatment of Alzheimer’s Disease: Comparing Guidelines
162nd Annual Meeting, San Francisco, California, USA
Severe Alzheimer Disease Responds Well to the 13.6 mg/24 hour Versus the 4.6 mg/24 hour Rivastigmine Patch
166th Annual Meeting, San Francisco, California, USA
The Treatment of Alzheimer’s Disease: Comparing Guidelines
American Psychiatric Association, 162nd Annual Meeting, San Francisco, California, USA
Severe Alzheimer Disease Responds Well to the 13.6 mg/24 hour Versus the 4.6 mg/24 hour Rivastigmine Patch
American Psychiatric Association, 166th Annual Meeting, San Francisco, California, USA
Join now to see all

Other

Clinical features and diagnosis of dementia with Lewy bodies
Farlow MR, Hake AM
http://www.uptodate.com/contents/clinical-features-and-diagnosis-of-dementia-with-lewy-bodies
UpToDate, Wolters Kluwer Health - 2013-02-06
Epidemiology, pathology, and pathogenesis of dementia with Lewy bodies
Farlow MR, Hake AM
http://www.uptodate.com/contents/epidemiology-pathology-and-pathogenesis-of-dementia-with-lewy-bodie
UpToDate, Wolters Kluwer Health - 2012-11-29
Prognosis and treatment of dementia with Lewy bodies
Farlow MR, Hake AM
http://www.uptodate.com/contents/prognosis-and-treatment-of-dementia-with-lewy-bodies
UpToDate, Wolters Kluwer Health - 2013-02-06

Cyclo Therapeutics Commences Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s DiseaseOctober 4th, 2022
Annovis Bio Inc. (ANVS) Stock Plunged During Current Market. Here’s the UpdateJuly 29th, 2021
NervGen Pharma : Expands Alzheimer's Disease Scientific Advisory BoardJuly 12th, 2021
Join now to see all

Core--ClinicalNational Institute On Aging2006–2010
Study Of AIT 082 In Mild Alzheimer'S Disease PatientsNational Center For Research Resources2000–2002
Core-- ClinicalNational Institute On Aging1994–2002
Ndd094 In 3 Cohorts For Mild To Moderate Alzheimers DiseaseNational Center For Research Resources1999
Phase I Study Of AIT 082 In Healthly Elderly VolunteersNational Center For Research Resources1998–1999